HR-8067-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Eugene Vindman (D-VA)
What it does
This bill would direct HHS, through the CDC, to run a grant program funding states to collect data on the incidence, prevalence, and healthcare use patterns of sickle cell disease, authorizing $10 million per year from 2027 through 2031. It would also require HHS to reinstate any employee of the CDC's Division of Blood Disorders and Public Health Genomics who was removed on or after January 1, 2025, as part of any workforce reduction or reorganization affecting 3% or more of that division's staff within a 60-day period.
Who benefits
People living with sickle cell disease and their families, who may benefit from better data-driven care and public health tracking; state health departments and researchers who would receive grant funding; and CDC employees in the Division of Blood Disorders and Public Health Genomics who were subject to a qualifying reduction in force and would be reinstated with their positions.
Who is hurt
Federal taxpayers who would fund the $50 million in grants over five years; HHS and CDC leadership, whose prior workforce reorganization decisions in this division would be reversed by statute, potentially complicating agency staffing plans; and any employees who may have been hired or reassigned to fill vacancies left by the removed employees, whose roles could be affected by reinstatement.
Supporters argue
Supporters argue that sickle cell disease disproportionately affects Black Americans and has historically been underfunded and understudied compared to other genetic conditions, so consistent national data collection is necessary to guide treatment and policy. They contend that reinstating removed Division of Blood Disorders staff restores institutional expertise and continuity that recent workforce reductions disrupted, ensuring ongoing surveillance work isn't lost.
Opponents argue
Opponents argue that Congress legislating the reinstatement of specific executive branch employees intrudes on the executive's personnel management authority and sets a precedent for statutory overrides of agency staffing decisions. They contend the $50 million authorization, while modest, adds to federal spending without offsetting cuts, and that mandating reinstatement regardless of the reorganization's underlying rationale ties HHS's hands in managing its workforce.
Constitutional context
Congress's authority to fund the data collection program rests on the Taxing and Spending Clause (Art. I, §8, cl. 1). The provision reinstating specific removed federal employees raises separation-of-powers questions about Congress directing personnel decisions within an executive agency, an area governed by the President's Article II authority to execute the laws and control subordinate officers, though Congress retains broad power to structure federal agencies and civil service protections.
Checks and balances
Congress would be exercising its spending and lawmaking power to both fund a program and directly override executive branch personnel decisions, narrowing HHS's discretion over staffing within a specific CDC division, with courts available to review any separation-of-powers challenge to the reinstatement mandate.
Historical precedent
The original CDC Sickle Cell Data Collection program, established through prior appropriations and public health initiatives, provides a direct precedent for this bill's data collection component, though the mandatory reinstatement of specific removed employees is a less common legislative approach.